PROTHENA CORP PUBLIC LTD CO - 10-Q Filing

Prothena Corp reports Q3 2026 results including ongoing R&D expenses and collaboration activities with Bristol Myers Squibb and Roche.

SEC EDGAR ·

Tickers: $PRTA

Read the full article at SEC EDGAR

More Regulatory news